anastrozole has been researched along with Arthropathies in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the joint symptoms and the impact on patients' health-related quality of life (HRQOL) due to 5 years of anastrozole from the baseline data in the N-SAS BC 05 trial, a randomized clinical trial was designed to assess the efficacy of 5 additional years of anastrozole among women with breast cancer." | 9.22 | Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. ( Iwase, T; Komoike, Y; Nakamura, T; Ohashi, Y; Ohtsu, H; Saji, S; Shimozuma, K; Takei, H; Yagata, H, 2016) |
| "Incidence of joint symptoms and bone fractures as well as changes in bone mineral density (BMD) in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole were investigated to determine whether there is an ethnic difference from Caucasian patients in the incidence of these adverse events of anastrozole." | 9.14 | Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. ( Kim, SJ; Noguchi, S; Okishiro, M; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y, 2009) |
| "A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)." | 7.83 | Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 6.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| "To assess the joint symptoms and the impact on patients' health-related quality of life (HRQOL) due to 5 years of anastrozole from the baseline data in the N-SAS BC 05 trial, a randomized clinical trial was designed to assess the efficacy of 5 additional years of anastrozole among women with breast cancer." | 5.22 | Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole. ( Iwase, T; Komoike, Y; Nakamura, T; Ohashi, Y; Ohtsu, H; Saji, S; Shimozuma, K; Takei, H; Yagata, H, 2016) |
| "Incidence of joint symptoms and bone fractures as well as changes in bone mineral density (BMD) in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole were investigated to determine whether there is an ethnic difference from Caucasian patients in the incidence of these adverse events of anastrozole." | 5.14 | Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole. ( Kim, SJ; Noguchi, S; Okishiro, M; Shimazu, K; Taguchi, T; Tamaki, Y; Tanji, Y, 2009) |
| "A total of 391 postmenopausal Japanese women with estrogen receptor-positive breast cancer and treated with adjuvant anastrozole were enrolled from 28 centers for assessment of patient-reported outcomes (PROs) in this prospective cohort study (SAVS-JP, UMIN000002455)." | 3.83 | Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes. ( Baba, M; Egawa, C; Hashimoto, T; Hidaka, T; Hirokaga, K; Ichii, S; Kikawa, Y; Kitatsuji, K; Kokufu, I; Konishi, M; Konishi, Y; Kono, S; Matsumoto, T; Minohata, J; Mitsunobu, M; Miya, A; Miyashita, M; Miyauchi, K; Miyoshi, Y; Nishikawa, H; Nishino, M; Oh, K; Okuno, T; Sakita, I; Sakoda, Y; Suwa, H; Takao, S; Wakita, K; Yamagami, K, 2016) |
| " The aim of this study was to assess the relative importance of different risk factors for treatment-emergent joint symptoms in patients assigned to anastrozole or tamoxifen as adjuvant treatment for postmenopausal breast cancer." | 3.74 | Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. ( Bianco, AR; Buzdar, AU; Cuzick, J; Eastell, R; Forbes, JF; Sapunar, F; Sestak, I, 2008) |
| "At our clinic from August 2001 to March 2005, 53 postmenopausal women with estrogen receptor-positive breast cancer were treated with anastrozole." | 3.73 | Joint symptoms: a practical problem of anastrozole. ( Inoue, K; Nagamoto, N; Nakahara, O; Ohsako, T; Sakamoto, N; Yoshida, Y, 2006) |
| "Fulvestrant is a new type of oestrogen receptor antagonist with no agonist effects." | 2.43 | Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents. ( Abram, P; Vergote, I, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yagata, H | 1 |
| Ohtsu, H | 1 |
| Komoike, Y | 1 |
| Saji, S | 1 |
| Takei, H | 1 |
| Nakamura, T | 1 |
| Ohashi, Y | 1 |
| Iwase, T | 1 |
| Shimozuma, K | 1 |
| Egawa, C | 1 |
| Hirokaga, K | 1 |
| Takao, S | 1 |
| Yamagami, K | 1 |
| Miyashita, M | 1 |
| Baba, M | 1 |
| Ichii, S | 1 |
| Konishi, M | 1 |
| Kikawa, Y | 1 |
| Minohata, J | 1 |
| Okuno, T | 1 |
| Miyauchi, K | 1 |
| Wakita, K | 1 |
| Suwa, H | 1 |
| Hashimoto, T | 1 |
| Nishino, M | 1 |
| Matsumoto, T | 1 |
| Hidaka, T | 1 |
| Konishi, Y | 1 |
| Sakoda, Y | 1 |
| Miya, A | 1 |
| Mitsunobu, M | 1 |
| Nishikawa, H | 1 |
| Kono, S | 1 |
| Kokufu, I | 1 |
| Sakita, I | 1 |
| Kitatsuji, K | 1 |
| Oh, K | 1 |
| Miyoshi, Y | 1 |
| Sestak, I | 1 |
| Cuzick, J | 1 |
| Sapunar, F | 1 |
| Eastell, R | 1 |
| Forbes, JF | 1 |
| Bianco, AR | 1 |
| Buzdar, AU | 1 |
| Okishiro, M | 1 |
| Taguchi, T | 1 |
| Kim, SJ | 1 |
| Tanji, Y | 1 |
| Shimazu, K | 1 |
| Tamaki, Y | 1 |
| Noguchi, S | 1 |
| Gheita, TA | 1 |
| Ezzat, Y | 1 |
| Sayed, S | 1 |
| El-Mardenly, G | 1 |
| Hammam, W | 1 |
| Vergote, I | 1 |
| Abram, P | 1 |
| Ohsako, T | 1 |
| Inoue, K | 1 |
| Nagamoto, N | 1 |
| Yoshida, Y | 1 |
| Nakahara, O | 1 |
| Sakamoto, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Effectiveness-implementation Trial for Evaluating Dietary and Manual Treatment With Osteopathic Techniques on Quality of Life and on Modulation of the Inflammatory State of Patients Diagnosed With Breast Cancer Undergoing Antiestrogenic Hormo[NCT06164119] | 600 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for anastrozole and Arthropathies
| Article | Year |
|---|---|
Fulvestrant, a new treatment option for advanced breast cancer: tolerability versus existing agents.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms | 2006 |
2 trials available for anastrozole and Arthropathies
| Article | Year |
|---|---|
Joint symptoms and health-related quality of life in postmenopausal women with breast cancer who completed 5 years of anastrozole.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; B | 2016 |
Incidence of joint symptoms and bone fractures in Japanese postmenopausal breast cancer patients treated with adjuvant anastrozole.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Asian People; Bone Density; Breast Neoplasms; Chemotherapy, | 2009 |
4 other studies available for anastrozole and Arthropathies
| Article | Year |
|---|---|
Risk factors for joint symptoms in postmenopausal Japanese breast cancer patients treated with anastrozole: a prospective multicenter cohort study of patient-reported outcomes.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Duct | 2016 |
Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; | 2008 |
Musculoskeletal manifestations in patients with malignant disease.
Topics: Adult; Aged; Analysis of Variance; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Comb | 2010 |
Joint symptoms: a practical problem of anastrozole.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Breast Neoplasms; Fema | 2006 |